ClinicalTrials.gg
RecruitingNCT07123805ACU_KneeUpdated Aug 14, 2025

ACU_Knee: Role of Acupuncture in Knee Prosthetic Surgery

An interventional study of Acupuncture group in Acupuncture Analgesia, Acupuncture and Acupuncture Therapy, sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-14.

Sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Apr 2024, registered Mar 2025).
  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Shoulder Pain with a site in Italy — 5 open to participants now, 5 under way, none of them phase 3. Shoulder Pain · Italy.

Planned enrollment
2nd of 11
80 · median 50
Started
2024
with 2 others
No phase
9 of 13
5 open now
Registered
9th of 13
by date
Lead sponsor
1 of 13
Fondazione IRCCS Policlinico San Matteo di Pavia

Among the 13 studies in Shoulder Pain with a site in Italy, this one is the 2nd largest by planned enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2024, is one of 9 with no phase, and was the 9th registered.

Shoulder Pain

738 studies on the registry are indexed under Shoulder Pain; 168 are open to participants now.

Browse Shoulder Pain studies →

Open to participants now

5 of the 13 studies in Shoulder Pain with a site in Italy are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 90 Shoulder Pain studies recruiting now, 25 (28%) set no upper age limit and 55 (61%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Shoulder Pain with a site in Italy, or all of them as a file.
02

Study summary

Post-operative analgesia after total knee arthroplasty (TKA) has always been a challenge in the anesthesiological setting, having to combine good pain control and the need for early mobilization, both factors that can affect the quality of rehabilitation treatment, prosthetic functional outcome, the onset of chronic pain, joint stiffness and the consequent quality of life of the patient. Recent loco-regional anesthesia (LRA) techniques have made an essential contribution to peri-operative management in the fast-track perspective of surgery, in terms of optimization of analgesia and rapid functional recovery. Inadequate post-operative analgesia, by affecting the normal rehabilitation pathway, is associated with medium-long term complications, such as chronic pain, joint stiffness and patient dissatisfaction, which often compromise functional autonomy and quality of life of the patient and may require invasive treatments (surgical revision, unlocking under general anesthesia). The local and systemic inflammatory state, evidenced by peri-operative dosage of specific biomarkers, appears to be related to prosthetic outcome.

Read the detailed description

Objectives, "The purpose of the study is to evaluate whether acupuncture, a technique recognized in the literature for its analgesic, anti-inflammatory and immunomodulatory effect, can affect: acute pain control and chronic pain prevention, functional outcome and subjective patient satisfaction. In particular, the investigators propose to define, through clinical evaluation and blood dosage of inflammation mediators, the anti-inflammatory effect of acupuncture, whether this affects the trend of inflammatory biomarkers and whether it can influence the functional result and the establishment of post-operative joint stiffness. Primary endpoint: to evaluate the efficacy of acupuncture on post-operative pain control at 36-48 hours after surgery, when moderate-severe pain occurs, due to the resolution of peripheral blocks. This role will be evaluated in relation to: total opioid consumption and the onset of side effects (nausea/vomiting, constipation, sedation), time out-of-bed and effect on the rehabilitation pathway, patient satisfaction. The medium/long-term functional outcome will be analyzed at one, three, six and twelve months after surgery. Secondary endpoint: to evaluate the effect of acupuncture on the modulation of systemic inflammatory response through the analysis of specific serum biomarkers and to evaluate their correlation with functional outcome and the onset of chronic pain." Inclusion/exclusion criteria Inclusion criteria: patients undergoing total knee replacement for primary osteoarthritic degeneration, elective monolateral surgery, patients capable of informed consent.

Exclusion criteria: age \< 18 years, total knee replacement for causes other than primary osteoarthritis (e.g. post-traumatic arthritis), revision surgery, contraindications to loco-regional anesthesia, contraindications to therapy with NSAIDs, cortisones and paracetamol, chronic assumption of opiates, use of corticosteroids in the six months prior to surgery, periarticular infiltration in the three months prior to surgery, patients with rheumatoid arthritis or autoimmune disorders, patients on therapy with biological drugs, ASA class > 3, pregnant women, active infection in antibiotic treatment.

Methods: Patients candidates for elective, monolateral, total knee replacement will be enrolled. The following data will be collected: demographic characteristics; comorbidities and psychological status (SF-12 score); pre-operative severity score (WOMAC Score); pre-operative pain assessment (NRS scale). For all patients, the anesthesiological treatment will be the one routinely used in the investigators' UOC : mild sedation with midazolam 1-2mg ev LRA subarachnoid with Levobupivacaine 0.5% 10-12mg tranexamic acid 1g ev. dexamethasone 4mg ev pre-operative analgesic block of the saphenous nerve with L-bupivacaine 0.5% 15ml, ultrasound-guided technique: pre-operative iPACK Block (Interspace between the Popliteal Artery and Capsule of the Knee) with L-bupivacaine 0.375% 20ml, ultrasound-guided technique; intraoperative analgesic therapy: Ketorolac 15mg + Paracetamol 1000mg ev post-operative analgesic therapy: paracetamol 1000mg ev every 8 hours; ibuprofen 400mg cp every 8 hours; tapentadol 50mg cp every 12 hours; rescue therapy (to be administered in case of NRS > 4): Oxycodone + Paracetamol 5/325mg, 1cp every 30 minutes, for a maximum of 4cp/day. Patients will be divided into two groups: Acu vs Standard. In the Standard group, the treatment will be the one described above. In the Acu group, acupuncture and auriculotherapy will be added to the standard treatment: patients will undergo three/four sessions of manual acupuncture lasting 20 minutes, the first in the immediate pre-operative period and the subsequent ones at a distance of 24, 48, 72 hours from surgery. The treatment includes manual acupuncture applied to specific points: LI4, LV3 and ST36 bilaterally and monolaterally SP6 and GB34, ipsilateral to the knee to be prostheticized. Furthermore, auricolar needles will be positioned, before surgery, for self-stimulation of the auriculotherapy points corresponding to Shen Men bilaterally and the knee point ipsilateral to the surgical side. The patient will be instructed on how to self-stimulate these auricular points during hospitalization. Patients will be evaluated at 24, 48, 72, 96 hours after surgery; post-operative parameters: evaluation of dynamic and resting pain (NRS scale), assumption of rescue analgesics; trend of vital parameters (HR, NIBP, RR, SpO2); incidence of adverse events and complications; functional outcomes: post-operative joint mobility parameters (ROM, Range of Motion, active and passive), time out-of-bed, resumption of ambulation, length of hospital stay (surgery-end of rehabilitation); patient-reported outcomes and related measures: Patient-Reported Outcome Measures (PROMs) and, specifically, Knee Injury and Osteoarthritis Outcome Score (KOOS); satisfaction questionnaire. In addition to biomarkers such as CRP and N/L ratio, routinely measured in the post-operative period, blood dosages of specific inflammation mediators (IL2 IL6 IL8 IL10 IFNy TNFa) will be performed in three moments: pre-operative, 48 hours and one month after surgery. The medium/long-term re-evaluation of enrolled patients will coincide with the outpatient checks normally prescribed, at a distance of one, three, six and twelve months post-TKA, and will include: evaluation of dynamic and resting pain (NRS scale); need for analgesic assumption; post-operative joint mobility parameters (ROM, Range of Motion, active and passive), patient-reported outcomes and related measures: Patient-Reported Outcome Measures (PROMs) and, specifically, Knee Injury and Osteoarthritis Outcome Score (KOOS); satisfaction questionnaire. In case the patient is unable to go to UOC for the checks scheduled after three months from surgery, the evaluation will take place by telephone.

03

Conditions studied

  • Acupuncture Analgesia
  • Acupuncture
  • Acupuncture Therapy
  • Total Knee Anthroplasty
  • Postoperative Pain Management
  • Pain Threshold
  • Shoulder Pain
  • Laparoscopies
  • Acupuncture Ear

Keywords

  • acupuncture
  • total knee arthroplasty
  • pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged > 18 years
  • Patients capable of providing
  • Unilateral total knee replacement surgery
  • Indication for surgery: primary osteoarthritis degeneration
  • Surgery performed electively

Exclusion criteria

Exclusion Criteria:

  • Patients aged \< 18 years
  • Patients incapable of providing
  • Patients with > 3
  • Pregnant women
  • Patients with rheumatoid arthritis or other disorders
  • Patients with active infection under antibiotic treatment
  • Patients on chronic opioid therapy
  • Patients on chronic biological drug therapy
  • Patients with a history of use in the six months prior to surgery
  • Patients with a history of periarticular infiltration in the three months prior to surgery
  • Patients in whom loco-regional anesthesia is
  • Patients in whom NSAID, cortisone, and paracetamol therapy is contraindicated
  • Bilateral total knee replacement surgery or prosthetic revision surgeries
  • Indication for surgery for causes other than primary osteoarthritis degeneration
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • No intervention
    Standard group

    the anesthesiological treatment will be the one routinely used at our UOC: mild sedation with midazolam 1-2mg ev LRA subarachnoid with Levobupivacaine 0.5% 10-12mg tranexamic acid 1g ev. dexamethasone 4mg ev pre-operative analgesic block of the saphenous nerve with L-bupivacaine 0.5% 15ml, ultrasound-guided technique: pre-operative iPACK Block (Interspace between the Popliteal Artery and Capsule of the Knee) with L-bupivacaine 0.375% 20ml, ultrasound-guided technique; intraoperative analgesic therapy: Ketorolac 15mg + Paracetamol 1000mg ev post-operative analgesic therapy: paracetamol 1000mg ev every 8 hours; ibuprofen 400mg cp every 8 hours; tapentadol 50mg cp every 12 hours; rescue therapy (to be administered in case of NRS \> 4): Oxycodone + Paracetamol 5/325mg, 1cp every 30 minutes, for a maximum of 4cp/day.

  • Active comparator
    Acupuncture group

    In the Acu group, acupuncture and auriculotherapy will be added to the standard treatment: patients will undergo three/four sessions of manual acupuncture lasting 20 minutes, the first in the immediate pre-operative period and the subsequent ones at a distance of 24, 48, 72 hours from surgery. The treatment includes manual acupuncture applied to specific points: LI4, LV3 and ST36 bilaterally and monolaterally SP6 and GB34, ipsilateral to the knee to be prostheticized. Furthermore, auricolar needles will be positioned, before surgery, for self-stimulation of the auriculotherapy points corresponding to Shen Men bilaterally and the knee point ipsilateral to the surgical side.

    Device: Acupuncture group

Interventions

  • DeviceAcupuncture group

    In the Acu group, acupuncture and auriculotherapy will be added to the standard treatment: patients will undergo three/four sessions of manual acupuncture lasting 20 minutes, the first in the immediate pre-operative period and the subsequent ones at a distance of 24, 48, 72 hours from surgery. The treatment includes manual acupuncture applied to specific points: LI4, LV3 and ST36 bilaterally and monolaterally SP6 and GB34, ipsilateral to the knee to be prostheticized. Furthermore, auricolar needles will be positioned, before surgery, for self-stimulation of the auriculotherapy points corresponding to Shen Men bilaterally and the knee point ipsilateral to the surgical side.

06

What researchers measure

Primary outcomes

  1. Quantity of opioid rescue medication taken by the patient

    Number of tablets taken daily and overall between 48 and 96 hours post-surgery

    Time frame: 48-96 hours

Secondary outcomes

  1. Time to first dose

    Time between surgery and the first dose of rescue opioid

    Time frame: one, three, six, and twelve months

Other outcomes

  1. Appearance of side effects related to opioid use during the first 96 hours of hospitalization

    Safety in terms of local tolerability in patients in the acupuncture treatment arm and systemic adverse events

    Time frame: One, three, six, and twelve months

  2. Pain perceived by the patient according to the NRS pain assessment scale at rest and dynamic

    Time frame: One, three, six, and twelve months

  3. Patient's sleep quality

    Analysis of the relaxing effect and modulation on sleep quality during the first 96 hours of hospitalization using the Richards-Campbell Sleep Questionnaire

    Time frame: One, three, six, and twelve months

  4. Time out-of-bed

    The variation in the time interval between surgery and the resumption of standing

    Time frame: One, three, six, and twelve months

  5. The overall effect on the rehabilitation path

    Assessing the range of joint motion during active and passive physical therapy, and the resumption of independent walking

    Time frame: One, three, six, and twelve months

  6. Time to resume walking

    Time frame: One, three, six, and twelve months

  7. Analysis of Knee Injury and Osteoarthritis Outcome Score (KOOS)

    Time frame: One, three, six, and twelve months

  8. Analysis of the International Knee Documentation Committee (IKDC) Subjective Knee Form

    Time frame: One, three, six, and twelve months

  9. The potential effect of acupuncture on modulating the systemic inflammatory response

    Blood dosage of specific inflammatory mediators

    Time frame: 48 hours and one month

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Dec 2026, 32 months after the start.

Of 351 non-industry interventional studies with no phase under Shoulder Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's planned 32 months is above that.

Counting every sponsor, half of 356 studies reached it within 11 months; a quarter within 4 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2025
First posted
Aug 14, 2025
StartActual
Apr 10, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07123805
Responsible party
Debora Passador (MD, Fondazione IRCCS Policlinico San Matteo di Pavia) — Principal investigator
First posted
Aug 14, 2025
Start date
Apr 10, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 14, 2025

Study contacts

Debora Passador, MD
Contact
d.passador@smatteo.pv.it
+390382502767

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion